RAPS Expands to Taiwan
RAPS announced a new chapter in Taiwan, which is its first in Asia.
The Regulatory Affairs Professionals Society (RAPS) announced a new chapter in Taiwan, which is its first in Asia. The Taiwan Chapter, which started as an affiliate, has expanded to an official chapter, allowing it to offer additional resources and opportunities to the regulatory community in Taiwan.
RAPS has made a series of moves expanding its presence in Asia, including the opening of two new offices in Asia—a Pan-Asia office in Singapore, serving the entire Asia-Pacific region, and another in Shanghai, serving the regulatory community in China.
Taiwan Chapter membership is open to all who reside in Taiwan and are involved in regulatory affairs, quality or other functions related to healthcare product regulation. For information about how to join and membership benefits, contact the RAPS Taiwan Chapter via the web page at http://www.raps-in-taiwan.org.tw.
Read the full release here.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
